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ABSTRACT Current approaches to prevention of blood-borne infections in injection
drug users include referral to drug abuse treatment, access to sterile syringes, bleach
disinfection of injection equipment, and education about not sharing equipment. However,
rates of some blood-borne infections (e.g., hepatitis C virus) remain elevated among
injection drug users, especially early after initiation into injection drug use. With lower
infection rates in noninjectors and transition into injection drug use occurring most
commonly among these noninjectors, prevention of transition into injection drug use
as an additional step to reduce risk for acquisition and transmission of blood-borne
infections merits closer attention. 
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For prevention of human immunodeficiency virus (HIV) and other blood-borne infec-
tions among injection drug users, the traditional approach to prevention has been to
encourage abstinence facilitated with drug abuse treatment; for injection drug users
who could or would not quit use, the approach has been to use brand new sterile needles
and syringes, then safely discard used equipment with each injection. Should sterile
needles and syringes be unavailable, then not sharing equipment and disinfection of
equipment with bleach are recommended. This hierarchy of prevention has been in
place and is part of the recommendations issued by the US Public Health Service.1 
The basis for these recommendations was the recognition that transmission of
blood-borne infections among substance users occurred primarily through multiple
reuse of syringes,2,3 and that such reuse was caused by both ritual behavior involving
sharing of needles and legal and economic barriers to sterile syringe access.4,5 Along
with the expansion of drug abuse treatment programs and the advent of needle-
exchange programs or expanded syringe access through pharmacies,6 considerable
headway has been made in the reduction of incidence of HIV infection among injection
drug users. 
Although HIV rates among injection drug users have subsided in many US and
European cities,7 continued high incidence of other blood-borne infections remains
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a problem. Rates of hepatitis C virus (HCV) and, despite availability of an effective
vaccine, hepatitis B virus (HBV) infection in injection drug users are typically above
10/100 person-years and can exceed 35/100 person-years in the first several years
after initiating injection.8–13 Approaches are needed to address reduction of blood-
borne infection in this population. 
Continuing high rates of hepatitis B and C virus infection in injection drug
users, even in communities, have shown declines in HIV infection related to a number
of factors. First, levels of HBV and HCV viral loads exceed those measured for HIV
infection,14 suggesting a higher efficiency in transmission. Second, several studies
have shown that rates of transmission are elevated within the first few years after
initiation into injection, during a period of time when individuals are less likely to
self-identify as injection drug users and therefore seek prevention and treatment
services.15,16 Predictors of entering methadone maintenance and characteristics of
persons attending needle-exchange programs tend to include persons with an average
of 10 years of substance use,17,18 which is long after the first several years of injection
drug use, when many of these users become infected with HBV and HCV. Third,
recent studies have implicated drug preparation practices, such as sharing cookers,
in which drugs are mixed with water and heated, and sharing cotton, which is used
to filter out particulate matter, as sources for transmission of HBV and HCV
infection.19,20 Other practices have been studied, including reuse of rinse water
between injections that becomes contaminated with blood, and “backloading,”
which involves splitting drugs prepared in one cooker with transfer of prepared
drug from one syringe (which may be contaminated) to a second syringe. Others have
mentioned that reuse of blood-tinged tourniquets might be a source of contamination
for transfer of HBV or HCV.21 
Although there are numerous possible mechanisms for parenteral transmission
of HBV and HCV infection, such a detailed list of changes in practices is daunting
for persons who are already disrupted by heavy drug dependence. Adoption of
effective prevention practices is more likely when advice is uncomplicated through
modest sets of instructions. Recommending drug treatment and, for those who will
not or cannot stop drug use, single use of sterile syringes is easy, but the addition of
consistent use of sterile cookers, cottons, clean rinse water, new tourniquets, and so
on is probably beyond what can be expected, especially for those who are homeless
and otherwise lacking resources. 
Another approach to consider for reducing incidence of HBV infection is more
extensive use of HBV vaccine. While safe and effective vaccines have been avail-
able for over two decades, rates of vaccination among substance users remain
low.22,23 Programs that offer vaccine have shown that high completion rates can be
achieved.24,25 Additional efforts are needed to achieve adequate levels. Improved
access for individuals who are at risk but uninfected needs to be developed and
implemented. Given that the risk for infection is high early after initiation into
injection drug use, persons need to be accessed early or even before they initiate
injection drug use. 
In the absence of a vaccine for HCV infection, behavioral approaches are
needed. Because the risk for infection is highly associated with injection drug use
and the risk is particularly high after initiation of injection, approaches are needed
that access these drug users early or even before they initiate injection drug use. In
our experience, accessing new-onset injection drug users is difficult, either directly
or through more experienced peers. Even with access, the epidemiology and behav-
ioral studies suggest multiple routes (e.g., sharing of needles, cookers, cottons, rinse
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water, backloading) may be involved, so instruction is likely to be complex and
tedious; consistent success is difficult to achieve. 
Several groups have started to examine risk factors for initiation into injection
drug use.26–28 Several findings are noteworthy. First, injection drug users tend to
transition from using noninjection drugs such as snorted heroin and cocaine or the use
of crack; although some transition without using these drugs, over 85% do.29 When
these new transition injection drug users were compared to their age-appropriate
peers who responded to the National Household Survey on Drug Abuse,30 they
were much more likely to have sniffed, snorted, or smoked heroin and cocaine
(including crack), with the usage rates of marijuana, hallucinogens, and inhalants
similar. Similarly, the proportions of the national survey sample that used noninjection
forms of heroin and cocaine were under 3%. 
Together, these data suggest that messages targeted to prevent transition to
injection drug use can be efficiently targeted within the population to a tiny subsample
at high risk for transition. This subsample consists of persons who have already
started noninjection drug use. Currently, outreach efforts to educate this population
about risk for health problems and treatment options have lagged behind efforts for
injection drug users. Second, prevalence of HCV infection of 52% in recent-onset
injectors has been reported31; we have shown,32 among a sample of heroin and
cocaine noninjectors from the same community, that the prevalence was 5%, which
is consistent with other studies showing that rates of HCV (as well as HIV) are
considerably higher in injectors than noninjectors. In New York City, the estimated
incidence of HCV infection was 10–35/100 person-years for new-onset injectors, and
0.45/100 person-years for a cohort of noninjectors followed in the same community.33 
These data suggest that an important message for HCV prevention that can be
achieved through outreach to noninjection drug users is to prevent transition into
injection drug use. Although the most important message might be cessation of sub-
stance use altogether, a secondary message would be to emphasize the importance
of not transitioning into injection. Most of HCV and much of HBV and HIV as well
as other blood-borne infections could be prevented by stopping transition into
injection drug use. 
Preventing transition into injection drug use is not the same as primary prevention
of substance use. Programs have been started in communities to prevent initial use of
any illicit substances, with varying levels of success.34 Clearly, success in these programs
would be important for public health and needs to be encouraged. Prevention of
transition into injection is a more focused effort to reach persons who have already
started noninjection drugs and may already be dependent. The goal of transition pre-
vention is to reduce or limit consequences of substance use and abuse that have
already started, but have not yet progressed to injection. They are not contradictory,
and both are part of a comprehensive program for infection prevention. 
Resistance to achievement of preventing transition into injection from noninjection
drug use is a problem that needs to be considered. One of the main reasons for tran-
sition is that injection is more efficient for dose delivery than sniffing or smoking
(for which part of the dose flakes or wafts away), and injection becomes more enticing
when the purity of drug drops or the cost of the drug escalates. In New York City,
the current high purity and low cost of illicit drugs35 make transition prevention
messages more palatable; how long these conditions will remain is unknown. The
message is probably reasonable to try for persons who have not yet transitioned
because they have yet to experience injection, and risk of consequences might be
ingrained without the trade-off of experience of injection and what that entails. 
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The message would appear relevant also to injection drug users who test negative
for HCV and other blood-borne infections; however, this is complicated for several
reasons. First, resistance to this message is likely to be higher for current injectors
because the issue of efficiency of dose delivery would be expected to be a more
formidable trade-off for the experienced injector (than the uninitiated) to make.
The type of drug, cocaine and heroin, may present additional important differences.
For example, the ease of getting heroin injectors to switch to snorting or “chasing
the dragon” (i.e., inhaled smoke) is unknown, but likely easier than doing the same
for cocaine injectors, particularly for smoking crack, which has a negative image
among many users. Also, primary prevention of injection is ethically more clear
than changing from injection to noninjection because, although injection is associated
with considerable risks for blood-borne infections, noninjection is not without risks
(such as increasing the risk for pneumonia).36 
Another concern to consider for injection prevention messages is whether tell-
ing a noninjector that he or she can reduce the risk for consequences of drug use
will produce a lower likelihood of curtailing drug use. The reasoning behind this
concern might be that telling a person that he or she can avoid consequences by
continuing what he or she currently does could have an unintended reinforcing
message. The argument is flawed for several reasons. First, the transition prevention
message, like primary substance abuse prevention, educates people about risks to
avoid for behaviors they have not started (or if they are at the experimental early
phases, have not yet suffered consequences). This does not condone current lifestyle
choices, but educates about directions to avoid that have even greater consequences.
Second, the experience with needle exchange with injection drug users started with
concerns that education about options might result in higher or more sustained
levels of drug use; these concerns were not borne out during evaluations across
multiple programs.6 Together, these considerations suggest that transition prevention
messages coupled with education about consequences of noninjection drug use and
options for treatment would represent a direction in prevention of infections that is
more comprehensive than approaches currently used. 
Efforts to develop interventions to prevent initiation or relapse into injection
have been scant.37–39 One randomized trial demonstrated effectiveness even with a
limited sample size39; however, consideration of widespread testing of transition
prevention messages has yet to receive adequate attention. The case for improving
information about identification of persons at risk for initiation into injection to
develop and evaluate new interventions to prevent transition makes sense, and the
time to move forward with this is now. 
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